The effect of formoterol on peritoneal VEGF levels in rats with endometriosis

Nafiye Yılmaz, Nafiye Yilmaz, Ozaksit G, Gulnur Ozaksit, Gülnur Özakşit, Keskin R, Raziye Keskin, Ömer Lütfi Tapısız, Omer Tapisiz, Leyla Mollamahmutoğlu, Mollamahmutoglu L, Leyla Mollamahmutoglu, Uysal S, Sema Uysal, Astarci M, Muzeyyen Astarci, Müzeyyen Astarcı, Hüseyin Üstün, Huseyin Ustun, Ustun H, Mulazımoglu B, Baris S. Mulazimoglu, Baris Mulazımoglu
Cytokine · 2012 · vol. 58(1) , pp. 47–49 · doi:10.1016/j.cyto.2011.12.014 · PMID:22265022 · W2043400307
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-11 ⓘ

This study investigated how formoterol impacts peritoneal vascular endothelial growth factor (VEGF) levels in a rat model of endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AimThe aim of this study is to investigate the effect of formoterol (β2 adrenergic receptor agonist) on peritoneal VEGF levels in rats with endometriosis.Materials and methodsExperimental endometriosis was constituted with implantation of endometrial tissue. The implants were examined by second laparatomy and rats were divided randomly into four groups. One cc saline was applied ip to the control (C) group (n=8) daily, 22.5μg/kg/day ip formoterol was applied to the second (F) group (n=10) daily, 22.5μg/kg/day ip formoterol and 10mg/kg/day ip propranolol were applied to the third (FP) group (n=10) daily, 45μg/kg/day ip formoterol was applied to the fourth (FF) group (n=9). Before treatment and after 30 days treatment period, peritoneal VEGF levels, the volumes and histopathological properties of the implants were evaluated.ResultsThere were significant differences in between the peritoneal VEGF levels before and after treatment in group 2(F) and group 4(FF) (p(a): 0.01, 0.01 respectively). But there were no significant changes in between the volumes of implants before and after treatment among the groups (p>0.05). There were no significant differences among the groups in histopathological parameters (p>0.05).ConclusionFormoterol treatment was seen to have no effect on the volumes and histopathological structure of endometriotic implants in our study. On the other hand, based on the group 2(F) and 4's (FF) VEGF levels after the treatment, low dose or high dose formoterol may be effective with long term therapy. Formoterol may reduce the development of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Adrenergic beta-2 Receptor Agonists Endometriosis Ethanolamines Vascular Endothelial Growth Factor A Adrenergic beta-2 Receptor Agonists Animals Endometriosis Endometriosis Endometriosis Ethanolamines Female Formoterol Fumarate Peritoneum Peritoneum Rats Rats, Wistar Vascular Endothelial Growth Factor A

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

Cited by (5)

Source provenance

europepmc
last seen: 2026-08-11T06:11:44.160905+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:16:23.388809+00:00
License: CC0 · commercial use OK